Q-omics provides the consensus-scored PMS2P7 profile across patient tissues and cancer cell-line models. PMS2P7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PMS2P7 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, PMS2P7 RNA expression shows 16,871 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, HNSC, and THYM as cancer lineages where PMS2P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMS2P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMS2P7 survival associations across molecular data types. PMS2P7 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMS2P7 RNA expression–survival associations across cancer types. High PMS2P7 expression shows unfavorable associations in LUAD, LGG, KICH and UVM, but favorable associations in UCS and ESCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for PMS2P7 RNA expression.
This table summarizes PMS2P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PMS2P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMS2P7 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, STAD, LUSC and LIHC. The HNSC box plot shows higher PMS2P7 RNA expression in tumor versus normal tissue (log2 FC = +0.150, t-test p < 0.001).
This table shows molecular features associated with PMS2P7 in patient tissues and cancer cell lines. In patient samples, PMS2P7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PMS2P7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
